This disclosure relates to novel scheme, it is used to handle an inflammatory arthritis, such as ankylosing spondylitis (AS) or psoriatic arthritis (PsA), it uses an IL-17 kind antagonists, such as 1L-17 binding molecules (such as, IL-17 antibody or its antigen-binding fragment, such as secukinumab) or IL-17 receptor binding domain molecule (for example, IL-17 antibody or its antigen-binding fragment) effective dose.
